Riken Corporation

Rin Institute Inc.

National Cancer Center Japan

The University of Tokyo

National Cancer Center

Nanocarrier Co., Ltd.

Shino Manabe

Yasuhiro Matsumura

Yukishige Ito

Masahiro Yasunaga

Kazunori Kataoka

Nobuhiro Nishiyama

Yasuki Kato

Yutaka Miura

Shingo Hanaoka

Shinji Saijou

Ryo Tsumura

Hirobumi Fuchigami

Yoshikatsu Koga

Yoshiyuki Yamamoto

Ryuta Sato

Kazuyuki Ishii

Yoshito Ihara

Tomoyuki Sugioka

Takahiro Anzai

An object of the present invention is to provide an anticancer drug capable of treating cancer by finding a target molecule specifically expressed in cancer cells and by specifically acting on the target molecule, and to provide a cancer testing method including a step of measuring the target molecule in a sample. The present invention provides an anticancer drug containing, as an active ingredient thereof, an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof. In addition, the present invention provides a cancer testing method including a step of measuring the amount of TMEM-180 in a sample collected from a subject.

Anti-TMEM-180 antibody, anticancer drug and cancer testing method

The present invention relates to an antibody-drug conjugate (ADC) and a composition containing the conjugate for use in treating cancer. According to the present invention, provided are an ADC of an antibody specific to insoluble fibrin and a drug in which a linker linking the antibody and the drug has a plasmin cleavage sequence, and a pharmaceutical composition containing the ADC for use in treating cancer.

Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate

Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.

Anti-tissue factor monoclonal antibody

The present invention provides a compound represented by the following formula (1): wherein X1 and X2 each independently represent a hydrogen atom or a hydroxyl-protecting group; Y represents a C7-20 aralkyl group which may optionally have one or more substituents selected from a halogen atom, a lower alkyl group or a lower alkoxy group; and Z represents a halogen atom, a C1-4 alkylthio, or an arylthio group, or its corresponding sulfoxide group.

Sugar donor

This invention provides a method of producing a large amount of an &#x3b1;-form or &#x3b2;-form of N-pyranosyl-tryptophan having a specified structure and preparing an antibody therefrom. The method comprises a step of allowing a pyranose compound to react with a 3-pyrazyl-indole compound in the presence of a first base to obtain a 1-pyranosyl-3-pyrazyl-indole compound, and a step of treating the 1-pyranosyl-3-pyrazyl-indole compound with an acid, treating the resultant with a hydrogenation catalyst, and further treating the resultant with a second base to synthesize N-pyranosyl-tryptophan, thereby producing an antibody therefrom.

Method for producing glycosylated indole compound and antibody against the compound

It is an object of the present invention to provide a novel method for producing a peptide thioester. In the present invention, general peptide synthesis is performed on a solid-phase resin, carboxylic acid obtained after cutout is allowed to react with p-toluenesulfonyl isocyanate, and then the reaction product is alkylated, and is reacted with thiol. Thus, peptide thioester is simply synthesized under mild conditions.

Method for producing peptide thioester

Growing community of inventors

Tokyo, Japan

Shino Manabe